A
911.84
-8.10 (-0.88%)
| Previous Close | 919.94 |
| Open | 914.19 |
| Volume | 163,090 |
| Avg. Volume (3M) | 341,988 |
| Market Cap | 56,985,411,584 |
| Price / Earnings (TTM) | 40.45 |
| Price / Earnings (Forward) | 35.84 |
| Price / Sales | 13.34 |
| Price / Book | 7.97 |
| 52 Weeks Range | |
| Earnings Date | 23 Jul 2026 |
| Profit Margin | 40.26% |
| Operating Margin (TTM) | 17.50% |
| Diluted EPS (TTM) | 16.39 |
| Quarterly Revenue Growth (YOY) | 95.70% |
| Total Debt/Equity (MRQ) | 0.71% |
| Current Ratio (MRQ) | 7.29 |
| Operating Cash Flow (TTM) | -82.75 M |
| Levered Free Cash Flow (TTM) | -143.39 M |
| Return on Assets (TTM) | -0.21% |
| Return on Equity (TTM) | 17.36% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | argenx SE | Mixed | Bullish |
AIStockmoo Score
0.8
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | 4.0 |
| Average | 0.83 |
|
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Growth |
| % Held by Institutions | 55.54% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Sands Capital Management, Llc | 31 Mar 2026 | 340,285 |
| Bellevue Group Ag | 31 Mar 2026 | 313,000 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |